Roger Song
Stock Analyst at Jefferies
(3.91)
# 634
Out of 5,055 analysts
50
Total ratings
43.9%
Success rate
15.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $28.27 | +59.18% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $8.02 | +99.50% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $471.92 | +19.51% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.16 | +331.03% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.68 | +2,399.26% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $25.61 | +40.57% | 1 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Hold | $3 → $1.5 | $1.66 | -9.64% | 1 | Aug 5, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $41.40 | +30.43% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $8.77 | -31.58% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.28 | -5.30% | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $59.58 | -49.65% | 11 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.76 | +240.91% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.64 | +92.31% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $208.25 | +17.65% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.15 | +263.64% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $8.31 | -15.76% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $10.85 | +158.06% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $2.45 | +185.71% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $89.65 | -0.73% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $6.80 | +267.65% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $12.79 | +220.56% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $35.88 | -2.45% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $48.34 | +166.86% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $3.55 | +125.35% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $108.00 | -10.19% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $38.22 | +187.81% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.19 | +735.32% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.65 | +445.45% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $8.91 | -10.21% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.85 | +2,370.30% | 1 | Sep 2, 2020 |
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $28.27
Upside: +59.18%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $8.02
Upside: +99.50%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $471.92
Upside: +19.51%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.16
Upside: +331.03%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.68
Upside: +2,399.26%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $25.61
Upside: +40.57%
LAVA Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: $3 → $1.5
Current: $1.66
Upside: -9.64%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $41.40
Upside: +30.43%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $8.77
Upside: -31.58%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.28
Upside: -5.30%
Apr 11, 2025
Upgrades: Buy
Price Target: $15 → $30
Current: $59.58
Upside: -49.65%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.76
Upside: +240.91%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.64
Upside: +92.31%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $208.25
Upside: +17.65%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.15
Upside: +263.64%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $8.31
Upside: -15.76%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $10.85
Upside: +158.06%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.45
Upside: +185.71%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $89.65
Upside: -0.73%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.80
Upside: +267.65%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $12.79
Upside: +220.56%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $35.88
Upside: -2.45%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $48.34
Upside: +166.86%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $3.55
Upside: +125.35%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $108.00
Upside: -10.19%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $38.22
Upside: +187.81%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.19
Upside: +735.32%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.65
Upside: +445.45%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $8.91
Upside: -10.21%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $0.85
Upside: +2,370.30%